Why the study?
Does pre-treatment with statins reduce periprocedural myocardial damage in patients undergoing percutaneous coronary intervention?
Does pre-treatment with statins reduce periprocedural myocardial damage in patients undergoing percutaneous coronary intervention?
Answers are grounded in this paper and cite their sources.
Pre-treatment with high-dose statins before percutaneous coronary intervention is supported by evidence to reduce periprocedural myocardial damage, likely through pleiotropic anti-inflammatory effects.
Statins inhibit hepatic 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMCoAR), consequently suppressing cholesterol biosynthesis. Animal studies, epidemiologic studies, and clinical trials all support the low-density lipoprotein (LDL) hypothesis. The benefit of these statin drugs has greatly impacted treatment of cardiovascular diseases in primary and secondary prevention. Data from the results of Cholesterol Treatment Trialists’ (CTT) have proved that a reduction of 1 mmol/L in LDL cholesterol levels yields a consistent 23% reduction in the risk of major coronary events over 5 years. In addition, several clinical and basic science investigations have clearly demonstrated that statins may provide additional benefit besides LDL reduction. Statins exert a number of protective effects, including increasing nitric oxide bioavailability, improving endothelial function, stabilizing atherosclerotic plaque, reducing adhesion molecules (vascular cell adhesion molecule-1, intercellular adhesion molecule-1, and E-selectin), and decreasing circulating biomarkers of oxidative stress and inflammation, and inhibiting thrombogenic response, the so-called ‘pleiotropic effects’. 1)
No takes yet. Share an insight, caveat, or question.
Habon et al. (2016) conducted an editorial in Cardiovascular disease requiring percutaneous coronary intervention. Statins was evaluated.
Synapse has enriched 10 related papers. Consider them for comparative context: